Literature DB >> 29368230

Multiparametric ultrasound-targeted biopsy compares favorably to multiparametric MRI-transrectal ultrasound fusion-targeted biopsy on initial biopsy of men at risk for prostate cancer.

Pat F Fulgham1.   

Abstract

PURPOSE: The purpose this study is to evaluate the efficacy of multiparametric ultrasound-targeted biopsies in patients undergoing initial biopsy of the prostate for the suspicion of prostate cancer.
MATERIALS AND METHODS: A total of 167 patients who are biopsy naïve underwent multiparametric ultrasound-targeted biopsy of the prostate. All patients had a transrectal ultrasound which included gray-scale evaluation and color Doppler evaluation. 12-core biopsies were performed on all patients, based on sextant anatomy; however, all cores were directed toward visually abnormal areas of the prostate as identified by multiparametric ultrasound, when such areas were present.
RESULTS: Of 167 patients undergoing biopsy, a total of 111 (66.5%) were positive for cancer. Of these, 78 (70.3%) had a Gleason grade ≥ 7 and 33 (29.7%) had a Gleason grade ≤ 6. Of those undergoing radical prostatectomy 29 of 38 (76.3%) had biopsy Gleason grade ≥ 7, while nine of 38 (23.7%) had a Gleason grade ≤ 6. Only four of 38 (10.5%) patients who had final pathologic staging underwent surgical therapy for disease of low-malignant potential (Gleason ≤ 6).
CONCLUSION: On initial biopsy for prostate cancer, multiparametric ultrasound-targeted biopsy compares favorably to the published performance of multiparametric MRI-TRUS fusion-targeted biopsy in terms of positive biopsy rate and the detection of disease of low-malignant potential.

Entities:  

Keywords:  Multiparametric MRI of the prostate; Multiparametric ultrasound; Prostate biopsy; Prostate cancer diagnosis

Mesh:

Year:  2018        PMID: 29368230     DOI: 10.1007/s00345-018-2187-9

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  12 in total

1.  Trends in prostate cancer mortality among black men and white men in the United States.

Authors:  Kenneth C Chu; Robert E Tarone; Harold P Freeman
Journal:  Cancer       Date:  2003-03-15       Impact factor: 6.860

2.  Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification.

Authors:  Neil Mendhiratta; Andrew B Rosenkrantz; Xiaosong Meng; James S Wysock; Michael Fenstermaker; Richard Huang; Fang-Ming Deng; Jonathan Melamed; Ming Zhou; William C Huang; Herbert Lepor; Samir S Taneja
Journal:  J Urol       Date:  2015-06-19       Impact factor: 7.450

Review 3.  Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review.

Authors:  Massimo Valerio; Ian Donaldson; Mark Emberton; Behfar Ehdaie; Boris A Hadaschik; Leonard S Marks; Pierre Mozer; Ardeshir R Rastinehad; Hashim U Ahmed
Journal:  Eur Urol       Date:  2014-11-01       Impact factor: 20.096

4.  Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection.

Authors:  Jérémie Haffner; Laurent Lemaitre; Philippe Puech; Georges-Pascal Haber; Xavier Leroy; J Stephen Jones; Arnauld Villers
Journal:  BJU Int       Date:  2011-03-22       Impact factor: 5.588

5.  Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

Authors:  B F Hankey; E J Feuer; L X Clegg; R B Hayes; J M Legler; P C Prorok; L A Ries; R M Merrill; R S Kaplan
Journal:  J Natl Cancer Inst       Date:  1999-06-16       Impact factor: 13.506

Review 6.  Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.

Authors:  Jurgen J Fütterer; Alberto Briganti; Pieter De Visschere; Mark Emberton; Gianluca Giannarini; Alex Kirkham; Samir S Taneja; Harriet Thoeny; Geert Villeirs; Arnauld Villers
Journal:  Eur Urol       Date:  2015-02-02       Impact factor: 20.096

Review 7.  Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis.

Authors:  Ivo G Schoots; Monique J Roobol; Daan Nieboer; Chris H Bangma; Ewout W Steyerberg; M G Myriam Hunink
Journal:  Eur Urol       Date:  2014-12-03       Impact factor: 20.096

8.  Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.

Authors:  Morgan R Pokorny; Maarten de Rooij; Earl Duncan; Fritz H Schröder; Robert Parkinson; Jelle O Barentsz; Leslie C Thompson
Journal:  Eur Urol       Date:  2014-03-14       Impact factor: 20.096

9.  A Randomized Controlled Trial To Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy.

Authors:  Eduard Baco; Erik Rud; Lars Magne Eri; Gunnar Moen; Ljiljana Vlatkovic; Aud Svindland; Heidi B Eggesbø; Osamu Ukimura
Journal:  Eur Urol       Date:  2015-04-07       Impact factor: 20.096

Review 10.  Role of mpMRI of the prostate in screening for prostate cancer.

Authors:  Christopher J D Wallis; Masoom A Haider; Robert K Nam
Journal:  Transl Androl Urol       Date:  2017-06
View more
  2 in total

1.  Standards, innovations, and controversies in urologic imaging.

Authors:  Pat Fox Fulgham; Tillmann Loch
Journal:  World J Urol       Date:  2018-05       Impact factor: 4.226

Review 2.  Application of Multiple Ultrasonic Techniques in the Diagnosis of Prostate Cancer.

Authors:  Yushan Liu; Shi Zeng; Ran Xu
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.